#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Metformin in patients with chronic kidney disease and cardiovascular disease


Authors: Vladimír Uličiansky 1;  Zbynek Schroner 2
Authors‘ workplace: Via medica, s. r. o., Košice 1;  SchronerMed, s. r. o., Košice 2
Published in: Diab Obez 2019; 19(37): 45-53
Category:

Overview

Metformin is the first-line pharmacologic treatment for type 2 diabetes. Provided that the dose is adjusted for renal function, metformin treatment appears to be safe and still pharmacologically efficacious in moderate-to-severe chronic kidney disease. According to consensus report by ADA EASD 2018 advantages of metformin include its high efficacy, low cost, minimal hypoglycaemia risk when used as monotherapy, and the potential for some weight loss. UKPDS study have suggested a benefit for preventing cardiovascular disease. Metformin may lower risk for cardiovascular mortality compared with sulfonylurea therapy. Rare cases of lactic acidosis have been reported, usually in the setting of severe illness or acute kidney injury.

Received 13. 4. 2019

Accepted 10. 5. 2019

Keywords:

treatment – continuous glucose monitoring – cardiovascular disease – guidelines


Sources
  1. Gregg, EW, Sattar N, Ali MK. The changing face of diabetes complications. Lancet Diabetes Endocrinol 2016; 4(6):537–547. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(16)30010–9>.
  2. Činnosť diabetologických ambulancií v SR 2017. Národné centrum zdravotníckych informácií, Bratislava 2018, ZŠ-11/2018. Dostupné z WWW: <http://www.nczisk.sk/Documents/publikacie/2017/zs1811.pdf>.
  3. Uličiansky V, Schroner V, Némethyová Z et al. Personalizovaná medicína v diabetológii v kontexte odporúčaní ADA/EASD 2015. Forum Diab 2015; 4(2): 102–118.
  4. Uličiansky V, Lazúr I. Rozhodovací algoritmus v klinickej praxi (Vnútorný dialóg lekára). Vnitř Lék 1985; 31(4): 391–397.
  5. Okša A, Ponťuch P, Spustová V et al. Diabetická nefropatia: Diagnostika, prevencia a liečba. Odporúčané postupy Slovenskej nefrologickej spoločnosti a Slovenskej diabetologickej spoločnosti. Forum Diab 2013; 2(2; Suppl 1): 1–6.
  6. Ponťuch P, Lištiaková D, Černá K. Výskyt mikroalbuminúrie, klinickej proteinúrie a artériovej hypertenzie u diabetikov 2. typu na Slovensku. Diabetes a obezita 2004; 4(7): 41–48.
  7. Haluzík M, Rychlík I. Léčba diabetiků s chronickým onemocněním ledvin. In: Haluzík M, Rychlík I et al. Léčba diabetu u pacientů s onemocněním ledvin a jater. Mladá fronta: Praha 2012: 63–99. ISBN 978–80–204–2671–0.
  8. Uličiansky V. Prevencia alebo spomalenie progresie diabetickej nefropatie. Skutočnosť alebo fikcia? Via Pract 2016; 13(4): 144–148.
  9. Bailey CJ, Day C. Diabetes Therapies in Renal Impairment. Br J Diabetes Vasc Dis 2012; 12(4): 167–171. Dostupné z DOI: <https://doi.org/10.1177/1474651412458811>.
  10. Bailey CJ. Metformin. In: Umpierrez G (ed). Therapy for Diabetes Mellitus and Related Disorders. 6th ed. American Diabetes Association 2014: 341–358. ISBN 978–1580405096.
  11. American Diabetes Association Standards of Medical Care in Diabetes 2018. Diabetes Care 2018; 41(Suppl 1): S1-S59.
  12. Garber AJ, Abrahamson MJ, Barzilay JI et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocr Pract 2018; 24(1): 91–120. Dostupné z DOI: <http://dx.doi.org/10.4158/CS-2017–0153>.
  13. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3(1): 1–150.
  14. Davies MJ, Alessio DA, Fradkin J et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 41(12):2669–2701. Dostupné z DOI: <https://doi.org/10.1007/s00125–018–4729–5>.
  15. [UK Prospective Diabetes Study (UKPDS) Group]. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–865. Erratum in Lancet 1998; 352(9139): 1558.
  16. Maruthur NM, Tseng E, Hutfless S et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016; 164(1): 740–751. Dostupné z DOI: <http://dx.doi.org/10.7326/M15–2650>.
  17. Súhrn charakteristických vlastností lieku metformín (Siofor). Dostupné z WWW: <https://www.adc.sk/databazy/produkty/spc/siofor-500–990352.html>.
  18. Rena G, Hardie G, Pearson EW. The mechanisms of action of metformin. Diabetologia 2017; 60(9): 1577–1585. Dostupné z DOI: <http://dx.doi.org/10.1007/s00125–017–4342-z>.
  19. Inzucchi SE, Lipska KJ, Mayo H et al. Metformin in Patients with Type 2 Diabetes and Kidney Disease: A Systematic Review. JAMA 2014; 312(24): 2668–2675. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2014.15298>.
  20. EMA/868987/2016. Použitie metformínu na liečbu cukrovky sa v súčasnosti rozšírilo na pacientov s mierne zníženou funkciou obličiek. V informáciách o lieku sa aktualizovali odporúčania pre pacientov s poruchou funkcie obličiek. Dostupné z WWW: <https://www.ema.europa.eu/medicines/human/referrals/metformin-metformin-containing-medicines>.
  21. Lalau JD, Kajbaf F, Bennis Y et al. Metformin Treatment in Patients with Type 2 Diabetes and Chronic Kidney Disease Stages 3A, 3B, or 4. Diabetes Care 2018; 41(3): 547–553. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–2231>.
  22. Ferrannini E, DeFronzo RA. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. Eur Heart J 2015; 36(34):2288–2296. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehv239>.
  23. Schroner Z, Uličiansky V. Metformín – súčasné postavenie v liečbe diabetes mellitus 2. typu a diskutované otázky ohľadom jeho použitia. Via Pract 2015, 12(4): 152–154.
  24. Uličiansky V. Metformín a kardiovaskulárne riziko. In: Schroner Z, Haluzík M, Mráz M et al. Antidiabetiká a kardiovaskulárne riziko. SchronerMED: Košice 2017: 34–50. ISBN: 978–80–8129–073–2.
  25. Maruthur NM, Tseng E, Hutfless S et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2016; 164(11): 740–751. Dostupné z DOI: <http://dx.doi.org/10.7326/M15–2650>.
  26. Chang S-H, Wu L-S, Chiou M-J et al. Association of metformin with lower atrial fibrilation risk among patients with type 2 diabetes mellitus: a population-based dynamic cohort and in vitro studies. Cardiovasc Diabetol 2014; 13: 123. Dostupné z DOI: <http://dx.doi.org/10.1186/s12933–014–0123-x>.
  27. Eurich DT, Weir DL, Majumdar SR et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: systematic review of observational studies involving 34 000 patients. Circ Heart Fail 2013; 6(3): 395–402. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCHEARTFAILURE.112.000162>.
  28. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129–2200. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw128>.
  29. Kirchhof P, Benussi S, Kotecha D et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37(38): 2893–2962. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehw210>.
  30. Fitchett D, Inzucchi S, Cannon Ch et al. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. Circulation 2019; 139(11): 1384–1395. Dostupné z DOI: <http://dx.doi.org/10.1161/CIRCULATIONAHA.118.037778>.
Labels
Diabetology Obesitology
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#